Daily Alert – 3/16/20
In the largest insider purchase of this year, the Non-Executive Chairman of the Board, John Gibson, recently bought US$497k worth of stock, paying US$39.11 for each share.
Read More
By the time I was a mere 20 years old, I was establishing myself as a financial planner, having already started working with a local firm in my home town of Binghamton, New York. Among other things, I became licensed as a General Securities Principal of our firm’s brokerage arm, supervising operational activitiesAlready becoming successful as both a manager and financial advisor, I was nevertheless quite unprepared for some of the massive market shifts of the early 1980’s. Successful strategies that had helped our clients reap huge rewards during the inflationary times of the late 1970’s particularly were turned upside down as interest rates skyrocketed and many previously-hot assets CRASHED.What STUNNED me was the fact that — though we can look back now at that change in Federal Reserve policy under then-Chairman Paul Volcker as one of the most abrupt in the central bank’s century in existence — NOBODY saw fit to do anything but continue to sell the same investment products. As with virtually everyone in the financial industry, you see, I had been trained in selling financial products and generating commissions; not in truly understanding the economy and markets.This experience first taught me that I needed to understand what I have since come to call “The Game” of our fractional reserve banking systemand how it and related factors create often-foreseeable swings inmarkets and asset classes. And it is this knowledge, together with specific, actionable strategies and investment recommendations, that I make available tomy Members on an ongoing basis. (NOTE: An archived version of my signature essay on all this, entitled Understanding the Game, can be accessed onmy web site, at http://nationalinvestor.com/)With this foundation, I am happy to tell you that The National Investor has become recognized as a leading source of credible, understandable information, commentary and investment strategies for individual investors. Often times, our performance has had us at the very top of the rankings put out by the well-known Hulbert Financial Digest, which has covered us since 2000._______________________________________________________________In addition to spending some time at The National Investor web site, you can follow me: On Twitter On Facebook On my YouTube channel
In the largest insider purchase of this year, the Non-Executive Chairman of the Board, John Gibson, recently bought US$497k worth of stock, paying US$39.11 for each share.
Read More
This lithium producer is poised to break out with a potential major source.
Read More
With a new government strategy for increasing domestic production and a mine with a long life, analysts expect this lithium producer to grow at a rate of 27.7% next year.
Read More
This regional supermarket also gets a nod from Zacks, scoring an ‘A’ on its VGM (value, growth, momentum score)
Read More
This gene therapy company has been getting lots of good attention from analysts, with coverage of the shares being initiated at Evercore ISI Group, with an ‘Outperform’ rating.
Read More
The shares of this company—in the midst of a turnaround—were recently upgraded at Jefferies, to ‘Buy’ and initiated at Mizuho, with a ‘Buy’ rating.
Read More
This dredging company just announced a $48 million base contract award on the Big Bend Channel of the Port of Tampa Bay, from the United States Army Corps of Engineers.
Read More
Our second recommendation is a sale on a company that is not living up to its promise.
Read More
Though the shares of this marijuana-related company have retreated a bit, its new collaboration offers an opportunity to participate in this growing sector at a discounted value.
Read More
For its latest quarter, this grocer’s net sales climbed to $1.03 billion (from $984.4 million) and net income totaled $24.5 million vs. $11.5 million for the third quarter of 2017.
Read More
This agriculture company turned in a stellar quarter, with adjusted EBITDA of $61.9 million in 1Q18, a 38.4% increase, year over year.
Read More
Only lost 27 cents per share in the latest quarter.
Read More
This fund seeks investment results that correspond (before fees and expenses) generally to the price and yield performance of its underlying index.
Read More
This investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the NASDAQ-100 Index®.
Read More
After a selloff, this REIT is looking very undervalued. The shares have a current dividend yield of 6.93%, paid quarterly.
Read More
Despite weak analyst sentiment, this biotech is looking healthy for the new year.
Read More
These two ideas are a bet on a better year for natural gas—whether you are a conservative or aggressive trader.
Read More
New FDA approvals are giving this stock some momentum.
Read More
This uranium company has several catalysts in store, and analysts are projecting double-digit growth this year.
Read More
This mining company beat analysts’ estimates by $0.02 last quarter. The shares have a current dividend yield of 5.05%, paid quarterly.
Read More